| 产品详情 |
| Edit |   |
|---|
| Product Name | Lapatinib, Di-p-Toluenesulfonate Salt |
|---|
| Description | Purity ~99%. Lapatinib inhibits both epidermal growth factor receptor (EGFR) and HER2/neu (ErbB-2) tyrosine kinases by binding to the intracellular phosphorylation domain, preventing receptor autophosphorylation. The exact site of binding has currently not been confirmed. It appears to arrest the development of breast cancer in some patients with metastatic, treatment-refractory disease. Solubility: Soluble in DMSO at 200mg/ml; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 1-10uM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Elemental Anaylsis: Calculated: C=54.22% H=4.76% Cl=3.72% F= 1.99% N=5.88% S= 10.10% |
|---|
| Size | 100mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | Lapatinib, Di-p-Toluenesulfonate Salt (N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Ditosylate, Lapatinib Ditosylate, Tykerb, GW-572016, Tyverb) |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | L1315-50 |
|---|
| Price | |
|---|
| Order / More Info | Lapatinib, Di-p-Toluenesulfonate Salt from UNITED STATES BIOLOGICAL |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|